Historically, pharmaceutical companies have relied on small molecules for most of their marketed products – usually as oral medication. However, large molecules (also known as biologics) are becoming increasingly important in revolutionizing the treatment of disease; delivering healing and hope to thousands of patients suffering from a range of illnesses including cancer, rheumatoid arthritis, and other immune disorders.
Biologics As A Strategic Priority
Biologics are increasingly important in the treatment of serious diseases and a growing part of the Bristol Myers Squibb portfolio of products and R&D pipeline. That’s why the company has made expanding its biologics manufacturing capacity and development capabilities a strategic priority.
An important effort is under way to continue to enhance our manufacturing and quality capability and enable our exciting pipeline of biologic drugs by building a strong science and engineering capability in our manufacturing organization.
Our success depends on building teams of bold, innovative and passionate employees who will help continue to drive us further forward. We need talented, dedicated people like you. We hope you’ll consider a position on our team.
Make a difference in our Biologics Division
- Commercial and Clinical Biologics Manufacturing
- Process Development
- Manufacturing Science and Technology
Bristol Myers Squibb is an equal opportunity employer. Qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, protected veteran status, pregnancy, citizenship, marital status, gender expression, genetic information, political affiliation, or any other characteristic protected by law. For our EEO Policy Statement, please click here. If you’d like more information on your EEO rights under the law, please click here. EEO is the LAW and Supplemental Information.